PedAM
Pediatric Disease Annotations & Medicines
| Disease | primary myelofibrosis |
| Symptom | C0002871|anemia |
| Sentences | 5 |
| PubMedID- 24636526 | Use of the functional assessment of cancer therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. |
| PubMedID- 24097336 | U2af1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with jak2v617f and normal karyotype. |
| PubMedID- 25897239 | Begna et al demonstrated the safety and therapeutic value of single-agent, low-dose pomalidomide in the treatment of anemia associated with jak2v617f positive myelofibrosis, particularly in the absence of splenomegaly. |
| PubMedID- 23748344 | Compounds that have demonstrated single-agent efficacy in clinical trials include immunomodulators such as pomalidomide (46), which alleviates the anemia associated with myelofibrosis, and drugs that affect remodeling of chromatin such as givinostat (47, 48). |
| PubMedID- 21052089 | In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (mf). |
Page: 1